Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated, commercial biotechnology ...

An edge comes to Michael’s voice when he speaks about his time serving in Afghanistan and his struggles living with ...

A mass shooting occurred in the small, seaside city of Southport on Sept. 27, and its impact may be felt for weeks or months ...

FOCUS is a randomized, double-blind, placebo-controlled crossover pilot study evaluating Tonix’s investigational intranasal potentiated oxytocin products in patients with Arginine-Vasopressin ...

FOCUS is a randomized, double-blind, placebo-controlled crossover pilot study evaluating Tonix's investigational intranasal potentiated oxytocin products in patients with Arginine-Vasopressin Deficien ...

A parent of a high school student has been reported for filing complaints accusing a teacher of human rights violations and child abuse after the teacher disciplined the student for smoking. On the ...

AFFIRM-1 trial did not meet primary endpoint or secondary endpoints Company to conduct strategic review of portfolio and business operations BURLINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ...

Topline results were announced from a phase 3 trial evaluating BNC210 in patients with social anxiety disorder.

The program in question is Neuphoria’s BNC210, also known as soclenicant, an α7 nicotinic receptor negative alteration ...

The American Heart Association has published a scientific statement regarding post-myocardial infarction psychological distress.

AFFIRM-1 trial did not meet primary endpoint or secondary endpoints Company to conduct strategic review of portfolio and business operations BURLINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Neupho ...

Neuphoria added it has an ongoing partnership with Merck & Co. under which MK-1167 is currently being evaluated in a Merck-led Phase 2 trial in Alzheimer's disease. Through the partnership, Neuphoria ...